"Maleimides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of maleimide (the structural formula H2C2(CO)2NH) containing a pyrroledione ring where the hydrogen atom of the NH group is replaced with aliphatic or aromatic groups.
| Descriptor ID |
D008301
|
| MeSH Number(s) |
D02.241.081.337.502.524 D02.478.440 D03.383.129.578.399
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Maleimides".
Below are MeSH descriptors whose meaning is more specific than "Maleimides".
This graph shows the total number of publications written about "Maleimides" by people in this website by year, and whether "Maleimides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Maleimides" by people in Profiles.
-
Annulation of Enals with Carbamoylpropiolates via NHC-Catalyzed Enolate Pathway: Access to Functionalized Maleimides/Iso-maleimides and Synthesis of Aspergillus FH-X-213. J Org Chem. 2021 07 16; 86(14):9466-9477.
-
Inhibitors of metalloprotease, ?-sectretase, protein kinase C and Rho kinase inhibit wild-type adenoviral replication. PLoS One. 2020; 15(7):e0236175.
-
G?6983 attenuates breast cancer-induced osteolysis by the apoptotic pathway. Cell Biol Int. 2020 Mar; 44(3):838-847.
-
Glycogen synthase kinase 3-? inhibition induces lymphangiogenesis through ?-catenin-dependent and mTOR-independent pathways. PLoS One. 2019; 14(4):e0213831.
-
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. Leuk Lymphoma. 2016 08; 57(8):1800-6.
-
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. Invest New Drugs. 2015 Dec; 33(6):1187-96.
-
Direct synthesis of chiral 3-arylsuccinimides by rhodium-catalyzed enantioselective conjugate addition of arylboronic acids to maleimides. Chemistry. 2015 Jul 27; 21(31):11050-5.
-
Protein kinase C inhibitor, GF109203X attenuates osteoclastogenesis, bone resorption and RANKL-induced NF-?B and NFAT activity. J Cell Physiol. 2015 Jun; 230(6):1235-42.
-
INPP4B suppresses prostate cancer cell invasion. Cell Commun Signal. 2014 Sep 25; 12:61.
-
Maleimide cross-linked bioactive PEG hydrogel exhibits improved reaction kinetics and cross-linking for cell encapsulation and in situ delivery. Adv Mater. 2012 Jan 03; 24(1):64-70, 2.